PeproMene, Bio

PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia in the Phase 1 Clinical Trial of PMB-CT01 at City of Hope

Published on 08/07/2025 at 18:06 | prnewswire.co.uk

PeproMene Bio, Inc. California

View original content:https://www.prnewswire.co.uk/news-releases/pepromene-bio-inc-announces-complete-remission-of-the-cohort-1-first-patient-treated-for-relapsed-and-refractory-b-cell-acute-lymphoblastic-leukemia-b-all-in-the-phase-1-clinical-trial-of-pmb-ct01-baffr-car-t-cells-at-city-o-302037392.html

en | boerse | 67953438 |